benzyloxycarbonyl-L-valyl-N-[(1S)-1-[[5-(3-methylbenzyl)-1,3,4-oxadiazole-2-yl]carbonyl]-2-methylpropyl]-L-prolinamide | 208840-22-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyloxycarbonyl-L-valyl-N-[(1S)-1-[[5-(3-methylbenzyl)-1,3,4-oxadiazole-2-yl]carbonyl]-2-methylpropyl]-L-prolinamide
• 英文别名: L-Prolinamide, N-((phenylmethoxy)carbonyl)-L-valyl-N-((1S)-2-methyl-1-((5-((3-methylphenyl)methyl)-1,3,4-oxadiazol-2-yl)carbonyl)propyl)-；benzyl N-[(2S)-3-methyl-1-[(2S)-2-[[(2S)-3-methyl-1-[5-[(3-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate
• CAS: 208840-22-6
• 化学式: C₃₃H₄₁N₅O₆
• 分子量: 603.718
• InChiKey: FPGAGACTKJTPFT-MYKRZTLLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  44
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Remedies for inflammatory bowel diseases
  申请人：——

  公开号：US20030212115A1

  公开（公告）日：2003-11-13

  Prophylactic and/or therapeutic drugs against ulcerative colitis, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, 1 (wherein Z represents the group containing &agr;-aminocarbonyl group, R 1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2) OH, (3) amino, (4) alkylamino, (5) dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  预防和/或治疗溃疡性结肠炎的药物，包括由式(I)表示的五元杂环化合物或这些无毒盐作为活性成分，其中Z代表含有α-氨基羰基的基团，R1代表(1)取代烷基、烯基或炔基基团，(2) OH，(3) 氨基，(4) 烷基氨基，(5) 二烷基氨基等，X和Y代表氧原子、硫原子或取代的氮原子。
• Airway mucus secretion inhibitors
  申请人：——

  公开号：US20030216324A1

  公开（公告）日：2003-11-20

  Prophylactic and/or therapeutic drugs against diseases with the augmentative airway mucus secretion, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, 1 (wherein Z represents the group containing &agr;-aminocarbonyl group, R 1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2)OH, (3)amino, (4)alkylamino, (5)dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  预防和/或治疗增多的气道粘液分泌疾病的药物，包括由式(I)所代表的五元杂环化合物或这些无毒盐作为活性原理，其中Z代表含有α-氨基羰基的基团，R1代表(1)取代烷基、烯基或炔基基团，(2) OH，(3) 氨基，(4) 烷基氨基，(5) 二烷基氨基等，X和Y代表氧原子、硫原子或取代的氮原子。
• Tri-peptide Inhibitors of Serine Elastases
  申请人：Cheronis John C.

  公开号：US20090156509A1

  公开（公告）日：2009-06-18

  The present invention provides compounds of formula (I): where X is R 1 —(CR 3 R 4 ) n OC(O)—; R 1 —(CR 3 R 4 ) n C(O)—; R 1 —C(O)NH(CR 3 R 4 ) n OC(O)—; R 1 —C(O)NH(CR 3 R 4 ) n C(O)—; R 1 —C(O)(CR 3 R 4 ) n OC(O)—; or R 1 —C(O)(CR 3 R 4 ) n C(O)—; where R 1 is optionally substituted C 5-10 aryl or heteroaryl; OH or NH 2 ; where R 3 and R 4 are independently H or methyl; and n is 0 to 6; and Y is —CF 3 or one of: where R 2 is C 1-8 alkyl optionally substituted with halo or —OH; —(CR 6 R 7 ) p —C 5-6 aryl optionally substituted with halo, —OH, C 1-8 alkyl, C 1-8 haloalkyl, —(CH 2 ) m C(O)NH 2 or —(CH 2 ) m OCH 3 ; where R 6 and R 7 are independently H or methyl; m is 0 to 4, and p is 0 or 1 or a pharmaceutically acceptable salt, ester, metabolite or prodrug thereof

  本发明提供了式(I)的化合物：其中X为R1—(CR3R4)nOC(O)—; R1—(CR3R4)nC(O)—; R1—C(O)NH(CR3R4)nOC(O)—; R1—C(O)NH(CR3R4)nC(O)—; R1—C(O)(CR3R4)nOC(O)—; 或R1—C(O)(CR3R4)nC(O)—;其中R1为可选择的取代C5-10芳基或杂环芳基; OH或NH2;其中R3和R4独立地为H或甲基; n为0到6;以及Y为—CF3或下列之一：其中R2为C1-8烷基，可选择地取代卤或—OH; —(CR6R7)p—C5-6芳基，可选择地取代卤，—OH，C1-8烷基，C1-8卤代烷基，—(CH2)mC(O)NH2或—(CH2)mOCH3;其中R6和R7独立地为H或甲基; m为0到4，p为0或1或其药学上可接受的盐，酯，代谢物或前药。
• REMEDIES FOR INFLAMMATORY BOWEL DISEASES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1323420A1

  公开（公告）日：2003-07-02

  Prophylactic and/or therapeutic drugs against ulcerative colitis, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, (wherein Z represents the group containing α-aminocarbonyl group, R1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2)OH, (3)amino, (4)alkylamino, (5)dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  溃疡性结肠炎的预防和/或治疗药物，其活性成分包括由式(I)代表的五元杂环化合物或这些无毒盐、 (其中 Z 代表含有α-氨基羰基的基团，R1 代表(1)取代的烷基、烯基或炔基，(2)OH，(3)氨基，(4)烷基氨基，(5)二烷基氨基等，X 和 Y 代表氧原子、硫原子或取代的氮原子）。
• AIRWAY MUCUS SECRETION INHIBITORS
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1323419A1

  公开（公告）日：2003-07-02

  Prophylactic and/or therapeutic drugs against diseases with the augmentative airway mucus secretion, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, (wherein Z represents the group containing α-aminocarbonyl group, R1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2)OH, (3)amino, (4)alkylamino, (5)dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  预防和/或治疗气道粘液分泌增多性疾病的药物，其活性成分包括由式(I)代表的五元杂环化合物或这些无毒盐、 (其中 Z 代表含有α-氨基羰基的基团，R1 代表(1) 取代的烷基、烯基或炔基，(2)OH，(3)氨基，(4)烷基氨基，(5)二烷基氨基等，X 和 Y 代表氧原子、硫原子或取代的氮原子）。